Zymeworks Launches $125M Share Repurchase Program
VANCOUVER, British Columbia, May 14, 2026 Zymeworks Inc. announced that its Board of Directors has approved a new 2026...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
VANCOUVER, British Columbia, May 14, 2026 Zymeworks Inc. announced that its Board of Directors has approved a new 2026...
VALENCIA, Calif., May 14, 2026 SetPoint Medical announced the publication of a peer-reviewed health economics study demonstrating that its...
